Kimmtrak
Payments companies reported to CMS as associated with Kimmtrak. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Kimmtrak, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Kimmtrak
These are the largest totals companies reported as associated with Kimmtrak. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Sushama Scalera | Salem, MA | Emergency Medicine | $233,583.65 |
| Geoffrey Gibney | Washington, DC | Internal Medicine | $75,490.74 |
| Yana Najjar | Washington, DC | $55,225.26 | |
| Sajeve Thomas | Orlando, FL | Hematology & Oncology | $48,433.56 |
| Omid Hamid | Santa Monica, CA | Hematology & Oncology | $48,228.05 |
| Inderjit Mehmi | Los Angeles, CA | Hematology & Oncology | $42,152.05 |
| Katherine Wang | Dallas, TX | Hematology & Oncology | $25,853.57 |
| Marlana Orloff | Philadelphia, PA | Medical Oncology | $22,342.84 |
| Nikhil Khushalani | Buffalo, NY | Medical Oncology | $19,260.63 |
| Richard Carvajal | New York, NY | Medical Oncology | $13,902.55 |
Prescribed Kimmtrak?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.